1. Efficacy of Combination Chemotherapy With Docetaxel, Estramustine and Carboplatin in Men With Castration-resistant Prostate Cancer
- Author
-
Hideto Iwamoto, Atsushi Takenaka, Ryutaro Shimizu, Shogo Teraoka, Bunya Kawamoto, Shuichi Morizane, Tetsuya Yumioka, Katsuya Hikita, Masashi Honda, and Panagiota Tsounapi
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Docetaxel/estramustine ,Combination chemotherapy ,Castration resistant ,medicine.disease ,Carboplatin ,chemistry.chemical_compound ,Prostate cancer ,chemistry ,Internal medicine ,medicine ,business ,Research Article - Abstract
Background: The efficacy of docetaxel and carboplatin with oral estramustine was evaluated in patients with castration-resistant prostate cancer. Patients and Methods: Patients were treated with intravenous docetaxel at 30 mg/m2 on days 1, 8, 15, and 22 of a 28-day cycle. Intravenous carboplatin (area under the curve, 6 mg/ml/min) was administered on day 1. Patients received oral estramustine at 626.8 mg/day throughout the treatment protocol. Patients were evaluated for response, with treatment continued until cancer progression or onset of severe adverse events. Results: Twenty patients with castration-resistant prostate cancer were treated for a median of 3.5 cycles. Prostate-specific antigen decreased by more than 30% in 18 patients, including 14 patients with a decrease of more than 50%. Median overall survival was 11 months, prostate-specific antigen progression-free survival was 6.5 months, and radiographic progression-free survival was 7 months. Conclusion: Docetaxel and carboplatin with oral estramustine shows efficacy against castration-resistant prostate cancer.
- Published
- 2021